BVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bioventus's average Accounts Payable for the three months ended in Dec. 2023 was $20.3 Mil. Bioventus's Cost of Goods Sold for the three months ended in Dec. 2023 was $49.1 Mil. Hence, Bioventus's Days Payable for the three months ended in Dec. 2023 was 37.78.
The historical rank and industry rank for Bioventus's Days Payable or its related term are showing as below:
During the past 9 years, Bioventus's highest Days Payable was 60.08. The lowest was 22.62. And the median was 32.07.
Bioventus's Days Payable declined from Dec. 2022 (49.27) to Dec. 2023 (37.78). It may suggest that Bioventus accelerated paying its suppliers.
The historical data trend for Bioventus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventus Annual Data | |||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Days Payable | Get a 7-Day Free Trial | 29.40 | 22.62 | 30.38 | 54.05 | 59.20 |
Bioventus Quarterly Data | ||||||||||||||||||||
Mar16 | Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Payable | Get a 7-Day Free Trial | 49.27 | 70.27 | 70.60 | 64.18 | 37.78 |
For the Medical Devices subindustry, Bioventus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioventus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioventus's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as
Days Payable (A: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2022 ) | + | Accounts Payable (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (36.697 | + | 23.038) | / | 2 ) | / | 184.152 | * | 365 |
= | 29.8675 | / | 184.152 | * | 365 | ||||
= | 59.20 |
Bioventus's Days Payable for the quarter that ended in Dec. 2023 is calculated as:
Days Payable (Q: Dec. 2023 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Sep. 2023 ) | + | Accounts Payable (Q: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | ( (17.637 | + | 23.038) | / | 2 ) | / | 49.122 | * | 365 / 4 |
= | 20.3375 | / | 49.122 | * | 365 / 4 | ||||
= | 37.78 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Bioventus's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Bihl Anthony P Iii | director, officer: Interim CEO | 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840 |
John A. Bartholdson | director, 10 percent owner | C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Juniper Investment Company, Llc | 10 percent owner | 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315 |
Katrina J Church | officer: SVP & Chief Compliance Officer | 3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303 |
Alexis P Michas | 10 percent owner | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Juniper Targeted Opportunities, Lp | 10 percent owner | 555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022 |
Juniper Targeted Opportunity Fund, L.p. | 10 percent owner | 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Mark Leonard Singleton | officer: SEE REMARKS | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
Anthony D'adamio | officer: SVP & General Counsel | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Kenneth Michael Reali | director, officer: Chief Executive Officer | 5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613 |
John Nosenzo | officer: Chief Commercial Officer | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Alessandra Pavesio | officer: SVP & Chief Science Officer | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Gregory O. Anglum | officer: SVP and CFO | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
Michelle Mcmurry-heath | director | C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703 |
From GuruFocus
By GlobeNewswire • 09-20-2023
By GuruFocus Research • 08-16-2023
By PRNewswire PRNewswire • 02-28-2023
By PRNewswire PRNewswire • 02-27-2023
By sperokesalga sperokesalga • 05-11-2023
By sperokesalga sperokesalga • 03-31-2023
By Marketwired • 09-20-2023
By sperokesalga sperokesalga • 05-23-2023
By Marketwired • 08-01-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.